Middle East conflict disrupts nearly 8,000 clinical trials |
| The conflict in Iran has disrupted nearly 8,000 clinical trial sites, according to a report from Phesi. The analysis covered over 65,000 global trials, revealing that 6.7% of active studies, or 4,361 trials, have been disrupted by the conflict in the affected region, impacting a total of 7,958 trial sites. Most disruptions occurred in Turkey, Israel, and Egypt, with oncology trials being significantly impacted. Phesi founder Gen Li emphasised the importance of patient safety amid these challenges, saying: "Patient safety and the safety of investigators and clinical staff must remain the primary consideration." |
|